Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Eltrombopag | Montmorillonite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Montmorillonite can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferasirox | Montmorillonite can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Montmorillonite. |
| Halofantrine | Montmorillonite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ursodeoxycholic acid | Montmorillonite can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Montmorillonite can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Montmorillonite can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Montmorillonite can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Montmorillonite can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Montmorillonite can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Obeticholic acid | Montmorillonite can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Montmorillonite can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Montmorillonite can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Montmorillonite can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Montmorillonite can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| cis-Diamminechlorocholylglycinateplatinum(II) | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Montmorillonite. |
| Dehydrocholic acid | Montmorillonite can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Montmorillonite can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aramchol | The serum concentration of Aramchol can be decreased when it is combined with Montmorillonite. |
| Ox bile extract | The serum concentration of Ox bile extract can be decreased when it is combined with Montmorillonite. |
| Technetium Tc-99m oxidronate | The serum concentration of Technetium Tc-99m oxidronate can be increased when it is combined with Montmorillonite. |
| Phenytoin | Montmorillonite can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mephenytoin | Montmorillonite can cause a decrease in the absorption of Mephenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Carbamazepine | Montmorillonite can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenobarbital | Montmorillonite can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Phenobarbital | Montmorillonite can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxadustat | Montmorillonite can cause a decrease in the absorption of Roxadustat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vadadustat | The serum concentration of Vadadustat can be decreased when it is combined with Montmorillonite. |